| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/19/2002 | WO2002072091A1 Anticancer drug-tolerance inhibitors |
| 09/19/2002 | WO2002072090A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| 09/19/2002 | WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | WO2002072032A2 Compounds and methods for identifying, staging and treating cutaneous t-cell lymphoma |
| 09/19/2002 | WO2002072027A2 Oncolytic rna replicons |
| 09/19/2002 | WO2002072021A2 Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| 09/19/2002 | WO2002072015A2 M cell directed vaccines |
| 09/19/2002 | WO2002072013A2 Method of treating malignancies through induction of blood immune responses |
| 09/19/2002 | WO2002072011A2 Stabilized therapeutic and imaging agents |
| 09/19/2002 | WO2002072010A2 Taxane prodrugs |
| 09/19/2002 | WO2002072009A2 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
| 09/19/2002 | WO2002072008A2 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 09/19/2002 | WO2002072003A2 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002059109A3 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002055095A3 Use of aziridino-compounds in the treatment of immune dysfunctions |
| 09/19/2002 | WO2002053534A8 Vla-4 inhibitors |
| 09/19/2002 | WO2002053184A3 Uses for polycationic compounds as vaccine adjuvants |
| 09/19/2002 | WO2002053138A3 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002033096A3 Regulation of human serine-threonine protein kinase |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002026730A3 Fluorinated quinolones as antimitotic and antitumor agents |
| 09/19/2002 | WO2002018553A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | WO2002014355A3 Novel mitogen activated kinase |
| 09/19/2002 | WO2002014311A3 Urea compounds and methods of uses |
| 09/19/2002 | WO2002010382A9 Trp8, trp9 and trp10, markers for cancer |
| 09/19/2002 | WO2002010379A3 Modified cea and uses thereof |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002005792A9 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 09/19/2002 | WO2002004953A3 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 09/19/2002 | WO2002004664A9 Genes comprising coding mononucleotide microsatellites or dinucleotide microsatellites that can be isolated from tumour cells |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2001092525A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 09/19/2002 | WO2001092299A9 Adenovirus particles with mutagenized fiber proteins |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001085208A8 Molecular antigen arrays and vaccines |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | WO2001036630A9 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 09/19/2002 | WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 09/19/2002 | WO2001030843A9 Ligand activated transcriptional regulator proteins |
| 09/19/2002 | WO2001019360A3 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 09/19/2002 | WO2001016139A9 Androgen receptor modulator compounds and methods |
| 09/19/2002 | WO2001007483A9 Prognosis and therapy of malignant diseases by antibodies which bind phosphorylated met protein |
| 09/19/2002 | WO2001007020A3 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof |
| 09/19/2002 | WO1997046589A3 Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods |
| 09/19/2002 | US20020133023 Antitumor agents, osteoporosis |
| 09/19/2002 | US20020133006 Nucleophilic replacement |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132976 Immunogenic peptides derived from prostate-specific antigen (PSA) and uses thereof |
| 09/19/2002 | US20020132849 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 09/19/2002 | US20020132842 Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132821 Novel heteroaryl derivatives and their use as medicaments |
| 09/19/2002 | US20020132820 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 09/19/2002 | US20020132816 Estrogen agonists/antagonists for preventing breast cancer |
| 09/19/2002 | US20020132811 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| 09/19/2002 | US20020132810 Novel heterocyclic amide derivatives |
| 09/19/2002 | US20020132807 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132795 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds |
| 09/19/2002 | US20020132778 Modulating angiogenesis |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132342 Generating immortalized dendritic cells; obtain cells, culture, maintain culture of dendritic cells, monitor gene expression from cell culture |
| 09/19/2002 | US20020132337 Processes for preparation of marek's disease virus using continuous avian cell lines |
| 09/19/2002 | US20020132334 Nucleotide sequences coding preferential polypeptide for use in the treatment of tumors and nervous system disorders |
| 09/19/2002 | US20020132329 ELL2, a new member of an ELL family of RNA polymerase II elongation factors |
| 09/19/2002 | US20020132324 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | US20020132319 Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 09/19/2002 | US20020132297 Nucleotide sequences coding protein for use in the treatment nflammatory bowel disease, sepsis, viral diseases and rheumatoid arthritis |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132275 Methods for detecting the efficacy of anticancer treatments |
| 09/19/2002 | US20020132237 Detecting ovarian cancer humans; obtain sample, incubate with preferential oligonucleotides, monitor hybridization, compare to control, evaluate for cancer |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020131968 An Immunoglobulin G (IgG) antibody with binding affinity for the CD3 antigen in which the heavy chain has a variable region framework together with specified complementary determining region (CDR); immunosuppressant, treating cancer |
| 09/19/2002 | US20020131967 Such as melphalan and an anti-interleukin-6 receptor antibody, administering in synergistic amounts |
| 09/19/2002 | US20020131966 Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs |
| 09/19/2002 | DE10112882A1 Selective cytostatic treatment of serotonin-producing tumors, using non-toxic tryptophan derivatives, e.g. 7-hydroxytryptophan, which are enzymatically converted into specific toxins in the tumor cells |
| 09/19/2002 | DE10112768A1 New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
| 09/19/2002 | DE10110754A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10110438A1 Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 09/19/2002 | DE10058461A1 Substituierte Cyclohexanderivate und ihre Verwendung Substituted cyclohexane derivatives and their use |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2473156A1 Rxr activating molecules |
| 09/19/2002 | CA2470152A1 Transfection complexes comprising a novel peptide as cell surface receptor binding component |
| 09/19/2002 | CA2458479A1 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof |
| 09/19/2002 | CA2441495A1 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | CA2441210A1 Novel peptide ligands of leukocyte integrins |
| 09/19/2002 | CA2441177A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| 09/19/2002 | CA2441088A1 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | CA2441082A1 Steap-related protein |
| 09/19/2002 | CA2440973A1 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |